Company profile for Genprex

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Genprex is a clinical stage gene therapy company committed to pioneering a new approach to treating cancer. We are developing potentially life-changing gene technologies based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow s...
Genprex is a clinical stage gene therapy company committed to pioneering a new approach to treating cancer. We are developing potentially life-changing gene technologies based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The nanovesicles are then administered intravenously and are taken up by tumor cells where they express proteins that are missing or found in low quantities.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Dell Medical Center Health Discovery Building 1601 Trinity Street, Bldg B Suit...
Telephone
Telephone
(877) 774-GNPX (4679)
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/genprex-provides-clinical-update-on-diabetes-gene-therapy-program-302654680.html

PR NEWSWIRE
07 Jan 2026

https://www.prnewswire.com/news-releases/data-from-genprexs-acclaim-1-phase-1-gene-therapy-clinical-trial-published-in-clinical-lung-cancer-302623852.html

PR NEWSWIRE
24 Nov 2025

https://www.prnewswire.com/news-releases/genprex-adds-clinical-trial-site-for-acclaim-1-and-acclaim-3-lung-cancer-clinical-trials-302619903.html

PR NEWSWIRE
19 Nov 2025

https://www.prnewswire.com/news-releases/genprex-announces-us-patent-for-reqorsa-gene-therapy-in-combination-with-pd-l1-antibodies-to-treat-cancers-302617555.html

PR NEWSWIRE
18 Nov 2025

https://www.prnewswire.com/news-releases/genprex-announces-european-patent-offices-intent-to-grant-a-patent-for-the-combination-of-reqorsa-gene-therapy-and-pd-1-antibodies-to-treat-cancer-302603759.html

PR NEWSWIRE
04 Nov 2025

https://www.prnewswire.com/news-releases/genprex-announces-registered-direct-offering-of-up-to-10-0-million-priced-at-the-market-under-nasdaq-rules-302597065.html

PR NEWSWIRE
28 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty